Founded in 1990 by scientist Dr. Tibor Sipos, Bethlehem-based Digestive Care, Inc. develops and manufactures pharmaceutical treatments for gastrointestinal disorders, including the PERTZYE pancreatic enzyme replacement therapy. The company’s work grew from Sipos’s patented microencapsulation technology for protecting digestive enzymes during gastric transit, and PERTZYE is manufactured in the USA by DCI.
ChiRhoClin, IncFounded in Maryland in 1991 by pharmacist and biopharmaceutics researcher Edward D. Purich, family-run ChiRhoClin develops peptide- and protein-based medicines for pancreatic and gastrointestinal disease. The company’s FDA-approved ChiRhoStim® synthetic human secretin supports pancreatic-function testing, gastrinoma diagnosis, and pancreatic imaging, while its research partnerships and grant program keep the focus on advancing pancreas science. ChiRhoClin also operates CRC Labs, an FDA-inspected cGMP laboratory with more than 50 years of combined pharmaceutical experience among its staff.BURTONSVILLE, MD
Per Os Biosciences LLCCreated in 2009 by a pharmaceutical industry executive, Per Os Biosciences grew from the acquisition of Koko’s Confectionery’s private-label manufacturing business. Today, its Maryland facility develops custom functional chewing gum for supplement and pharmaceutical brands, using proprietary direct-compression technology and an in-house powdered gum base.HUNT VALLEY, MD
Sigmapharm Laboratories, LLCFounded by Dr. Spiro Spireas in 2005, Sigmapharm Laboratories is a privately held specialty pharmaceutical company built around solving formulation problems that make certain medicines difficult to develop. From its Bensalem campus, the company researches and manufactures generic and branded drugs using proprietary delivery systems, then brings selected products to market under its own label.BENSALEM, PA
Pharmapotheca A, IncFounded by Harold Meckler and Karl Popp in 2014, Pharmapotheca A develops pharmaceutical chemistry technologies and supplies patent-protected compounds for chemical and pharmaceutical research. The Delmar company focuses on amphetamine-related synthesis, controlled-release and abuse-deterrent dosage-form technologies, with its intellectual property exclusively licensed in part from Chemapotheca. In 2020, synthetic organic chemist Thomas E. D’Ambra joined as CEO to guide the company’s expansion.DELMAR, NY